Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...
The narrower label for Zejula (niraparib ... after the company revealed that its BCMA-targeting drug Blenrep (belantamab mafodotin) failed to meet its objectives in a multiple myeloma study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback